Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours.

[1]  A. Shilkaitis,et al.  4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland. , 1999, Carcinogenesis.

[2]  J. Russo,et al.  Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. , 1980, Cancer research.

[3]  L L Vindeløv,et al.  A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. , 1990, Cytometry.

[4]  J. Shay,et al.  Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP) , 1995 .

[5]  J. Campisi.  The biology of replicative senescence. , 1997, European journal of cancer.

[6]  J. Shay,et al.  Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. , 2001, Journal of the National Cancer Institute.

[7]  S. Aaronson,et al.  Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Gusterson,et al.  Classification of Neoplastic and Nonneoplastic Lesions of the Rat Mammary Gland , 1989 .

[9]  K Watanabe,et al.  Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Wellstein,et al.  The efficacy of 9-cis retinoic acid in experimental models of cancer , 2005, Breast Cancer Research and Treatment.

[11]  G. Mills,et al.  Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition , 1997, Oncogene.

[12]  R. Toillon,et al.  Autocrine and paracrine growth inhibitors of breast cancer cells , 2000, Breast Cancer Research and Treatment.

[13]  G. Kelloff,et al.  Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozole , 2000, Breast Cancer Research and Treatment.

[14]  J. Sham,et al.  Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. , 1998, Cancer research.

[15]  M. Morrow,et al.  Tamoxifen, raloxifene, and the prevention of breast cancer. , 1999, Endocrine reviews.

[16]  V. Steele,et al.  Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. , 1998, Carcinogenesis.

[17]  O. Pereira-smith,et al.  Replicative Senescence: Implications for in Vivo Aging and Tumor Suppression , 1996, Science.

[18]  R. Reddel,et al.  Genetic changes associated with immortalization. A review. , 1997, Biochemistry. Biokhimiia.

[19]  G. Kelloff,et al.  Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. , 1999, Carcinogenesis.

[20]  J. Shay,et al.  Refining the telomere-telomerase hypothesis of aging and cancer , 1996, Nature Biotechnology.

[21]  D. Wallwiener,et al.  Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer , 1998, International journal of cancer.

[22]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Adami,et al.  Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts , 1998, Oncogene.

[24]  R. Schimke,et al.  Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[26]  S. Sukumar,et al.  Telomerase activity in the normal and neoplastic rat mammary gland. , 1997, Cancer research.

[27]  E. Kandel,et al.  A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. , 1999, Cancer research.

[28]  K. Matsumoto,et al.  Cell proliferation and advancement of hepatocarcinogenesis in the rat are associated with a decrease in connexin 32 expression. , 1995, Carcinogenesis.

[29]  F. Talamantes,et al.  Kinetics of mammary epithelial cell proliferation in pituitary isografted BALB/c mice. , 1993, Carcinogenesis.

[30]  A. Miller,et al.  Purification of human liver acid beta-D-galactosidases using affinity chromatography. , 1976, Analytical biochemistry.

[31]  D. Johnston,et al.  Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  A. Bednarek,et al.  Constitutive telomerase activity in cells with tissue-renewing potential from estrogen-regulated rat tissues , 1998, Oncogene.

[33]  V. Steele,et al.  Perspectives on chemoprevention agent selection and short-term clinical prevention trials. , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.